Tumor-associated glycoprotein 72 (TAG-72) is a large, high molecular weight, mucinlike antigen that is expressed in a wide variety of human carcinomas. Three different TAG-72 monoclonal antibodies (MAbs), designated B72.3, CC49, and CC83, were applied to the following archived samples from the dog: 1) 51 transitional cell carcinomas of the urinary bladder, 2) 1 5 hyperplasWinflamed urinary bladders, and 3) eight normal urinary bladders. Immunoreactivity was detected with an avidin-biotin complex immunoperoxidase method. Fifty-three percent (27/5 1) of transitional cell carcinomas were positive ( 2 5% staining) for MAb B72.3. MAb B72.3 staining of these transitional cell carcinomas did not statistically correlate with any of the examined features of malignancy, including histologic grade, clinical stage, DNA ploidy, or presence of vascular/lymphatic invasion. In regard to the staining of transitional cell carcinoma by the other two TAG-72 antibodies, 53% (27/ 51) of the samples were positive for MAb CC83 and 63% (32/51) were positive for MAb CC49. The finding that similar populations of neoplastic urothelial cells in serial sections from the same neoplasm stained with all three TAG-72 antibodies supports the hypothesis that an antigen similar to TAG-72 was expressed in canine transitional cell carcinoma. None of the normal urinary bladders nor any of the hyperplastic/inflamed urinary bladders stained with any of the three TAG-72 antibodies tested. The results of these studies demonstrated that the staining of canine transitional cell carcinoma with all three TAG-72 antibodies was specific for neoplastic urothelial cells and that an antigen similar to TAG-72 was expressed.
Tumor-associated glycoprotein 72 (TAG-72) is a large, high molecular mass glycoprotein (> 1 O6 daltons) that has biochemical and biophysical properties of mucin.9-25 The first monoclonal antibody (MAb) generated against TAG-72 was called B72.3.5 Many immunohistochemical studies have demonstrated that MAb B72.3 reacts with a majority of human carcinomas of the C O~O~,~~~~~ pancreas,14 mammary gland,2L,22 ovary,27 prostate, 16 and lung.lJo MAb B72.3 is nonreactive or only weakly reactive with most normal human tissues. '7,28 This antibody has been used in the diagnosis of human carcinoma in various modalities, including detection of carcinoma lesions in vivo using radiolabeled MAb B72.3,4,6 detection of TAG-72 in sera from patients with carcinoma via radioimmunoassay,I2 and immunocytochemical detection of cell-associated TAG-72 in fine needle aspirates and abdominal effusion^.'^^^^^^^ As a result of the purification of TAG-72, other second generation TAG-72 antibodies, including MAbs CC49 and CC83, were generated.l9 MAbs CC49 and CC83 appear to have the same range of tissue immunoreactivity as MAb B72.3;17J9 however, these two antibodies bind to different epitopes on TAG-72 than does MAb B72. 3.13 Because of its proven utility in the diagnosis of human carcinomas, MAb B72.3 was applied to five types of canine carcinoma^.^ In this preliminary immunohistochemical study, MAb B72.3 stained >50% ofpulmonary, nasal, and mammary adenocarcinomas and transitional cell and prostatic carcinoma^.^ These results from this study demonstrated that an antibody generated against a human tumor-associated antigen cross reacts with canine tissues and may be of diagnostic value.
To further evaluate the diagnostic and prognostic value of MAb B72.3 in veterinary medicine and to better define the antigen to which MAb B72.3 binds in canine carcinomas, we applied MAb B72.3 and two other TAG-72 antibodies, MAbs CC49 and CC83, to a large group of canine transitional cell carcinomas of the urinary bladder. Canine transitional cell carcinoma Clemo, DeNicola, Carlton, Walker, and Morrison Vet Pathol 32: 2, 1995 was chosen because it demonstrated specific and intense staining with MAb B72.3 in the preliminary immunohistochemical study. The objectives of this study were the following: 1) to validate the preference of MAb B72.3 for neoplastic urothelial cells, 2) to investigate the prognostic value of MAb B72.3, and 3) to characterize the distribution of antigen to which MAb B72.3 binds by using two other TAG-72 antibodies, MAbs CC49 and CC83.
Materials and Methods

Specimen collection and monoclonal antibodies
Canine tissues collected from the archives (1983-1990) of the Purdue University Comparative Oncology Program and the Indiana Animal Disease Diagnostic Laboratory included 51 transitional cell carcinomas of the urinary bladder, 15 hyperplastidinflamed urinary bladders, and eight normal urinary bladders. All tissues were fixed in neutral buffered 10% formalin and embedded in paraffin.
The histologic grade of each transitional cell carcinoma was determined according to Mostofi's three-grade system,,* and the clinical stage of each was determined according to the tumor, node, and metastasis (TNM) system currently approved for dogs by the World Health Organization. Because accurate data concerning tumor involvement of regional lymph nodes and distant organs was lacking, only the T (tumor) category of the TNM system was determined for each neoplasm. The DNA content (DNA ploidy) of 43 of 5 1 transitional cell carcinoma samples was also determined through the use of single parameter flow cytometry. The procedures for measurement of the DNA content and classification of DNA ploidy have been previously described., The neoplasms were also evaluated for the following morphologic features: 1) urothelial metaplasia (squamous or glandular), 2) vascular or lymphatic invasion, and 3) intraepithelial cytoplasmic vacuoles. MAbs B72.3, CC49, and CC83 (supplied by Dr. D. Johnson, Lilly Research Laboratories, Eli Lilly Co., Indianapolis, IN, and Dr. J. Schlom, National Institutes of Health, Bethesda, MD) are ascites-derived, affinity-purified murine IgG, immunoglobulins. MAb B72.3 was generated using a membrane-enriched fraction of human breast carcinoma (metastatic to liver) as an i m m~n o g e n .~ MAbs CC49 and CC83 were generated using purified TAG-72 from a human colon carcinoma xenograft as an immunogen. An affinity-purified murine IgG, myeloma protein called MOPC-21 (Sigma Chemical Co., St. Louis, MO) was used in place of the primary antibody as a negative control. All antibodies were used at a concentration of 17.8 &ml.
Immunoperoxidase method
The avidin-biotin complex (ABC) immunohistochemical method (Vectastain ABC kit, Vector Labs., Burlingame, CA) was used as previously described8 with slight modifications. Tissue sections ( 5 Km) were placed on slides coated with L-polylysine (Sigma), allowed to dry, and heated at 60 C for 15-20 hours. The sections were deparafinized in xylene and rehydrated in graded alcohols. Endogenous peroxidase activity was blocked by incubation with 0.3% H,O, methanol solution for 10 minutes. After washing with 0.15% bovine serum albumin (BSA) in phosphate-buffered saline (PBS), sections were incubated with 10% normal horse serum for 15 minutes. The horse serum and all subsequent reagents were diluted in PBS with 0.1% BSA and used at a volume of 200 pllslide. Serial sections from each sample were then incubated with MAbs B72.3, CC49, and CC83 for 20-24 hours at 4 C. A section from each sample was also incubated with MAb MOPC-2 1 instead of the primary antibody under identical conditions as the primary antibodies. A section of formalin-fixed, paraffin-embedded human ovarian adenocarcinoma, which stained consistently with MAbs B72.3, CC49, and CC83, was included as a positive control with each staining run.
After antibody incubation, sections were washed with 0.15% BSA in PBS and sequentially incubated with biotinylated horse anti-mouse IgG (Vector) at a 1 : 500 dilution and avidin DH : biotinylated horseradish peroxidase complex (Vector) for 30 minutes each, with rinses of 0.15% BSA in PBS between incubations. The slides were then rinsed in 0.15% BSA in PBS, and the peroxidase reaction was initiated by the addition of 0.06% diaminobenzidine (Sigma) and 0.0 1% H,O, for 5 minutes. Sections were counterstained with Mayer's hematoxylin (Sigma), dehydrated in graded alcohols, cleared in xylene, and mounted under a coverslip using Permount mounting media (Itasca, IL). All reagent incubations were carried out at room temperature unless otherwise specified.
All samples were evaluated microscopically for the presence of the brown diaminobenzidine stain indicative of antibody staining. The staining was evaluated for the following features: 1) staining intensity: 0 = negative, 1 = weak, 2 = moderate, and 3 = strong; 2) staining location: cytoplasmic, membranous, or extracellular; and 3) tissue staining patterns: diffuse, focal, and multifocal/random. The percentage of cellular staining of all samples was estimated semiquantitatively and expressed according to the following scale: 0 4 % , 5-24%, 25-49%, 50-74%, and 75-1 00%. Samples were considered positive for antibody staining when 2 5 % of the urothelial cells contained a distinct cellular stain.' All samples were examined by two independent observers (F.A.S.C., D.B.D.).
Neoplasms that were initially considered negative for MAb B72.3 (< 5% staining) or contained questionable staining results (5-6% staining) were restained with MAb B72.3. Before sections from these neoplasms were incubated with MAb B72.3, they were trypsinized with 0.1% porcine trypsin (Sigma) at 37 C for 15 minutes.
Statistical evaluation
Fisher's exact test (two-sided) was used to compare MAb B72.3 staining (negative versus positive) with histologic grade, clinical stage, DNA ploidy, and the presence of vacuoles, urothelial metaplasia, and vascular/lymphatic invasion. The level of significance was set at P < 0.05.
Results
Immunoreactivity of transitional cell carcinoma with MAb B72.3
In this study, 27 of 5 1 (53%) canine transitional cell carcinomas of the urinary bladder stained positively for MAb B72.3. A majority of positive neoplasms had cellular staining between 5% and 24%, with only one neoplasm having > 50% staining ( Table 1 ). The staining of the positive neoplasms was only observed in neoplastic urothelial cells (Fig. 1 ). Normal urothelium, stroma, muscle, and inflammatory cells did not stain. The staining of the neoplastic urothelial cells was moderate to marked in intensity and was commonly ob- * Samples were classified as positive for antibody staining when 25% of the neoplastic cells contained a distinct cellular stain. Staining t 1 = weak; 2 = moderate; 3 = strong.
$ D = diffuse; F = focal; M/R = multifocal or random.
was found in cytoplasm, membrane, and extracellular secretions.
served in the cytoplasm (Fig. 2) . In some neoplasms, cytoplasmic vacuoles and plasma membranes of neoplastic urothelial cells and extracellular secretions stained also. The multifocal pattern of tissue staining was observed most commonly in these neoplasms (Table 1). In this study, 24 of 51 canine transitional cell carcinomas of the urinary bladder were classified as negative for MAb B72.3 because <5% of the neoplastic cells stained. Of these 24 neoplasms designated as negative, six had low numbers of randomly distributed, weakly stained neoplastic urothelial cells. This staining pattern was easily differentiated from nonspecific background staining associated with the edges of the section; however, it was not distinct enough to allow classification of the sample as positive.
After trypsinization, six of seven questionably (5-6% cellular staining) stained neoplasms were considered positive for MAb B72.3. None of the 23 neoplasms initially classified as negative for MAb B72.3 were reclassified after trypsinization.
Positive staining of transitional cell carcinomas with MAb B72.3 did not statistically correlate with specific features of malignancy, including clinical stage, histologic grade, DNA ploidy, and the presence of vascular/lymphatic invasion, cytoplasmic vacuoles, or urothelial metaplasia ( Table 2) .
Immunoreactivity of transitional cell carcinoma with MAbs CC49 and CC83
Sixty-three percent (32/5 1) of the transitional cell carcinomas stained positively with MAb CC49, whereas 53% (27/5 1) stained positively with MAb CC83. As with MAb B72.3, cellular staining of a majority of neoplasms positive for MAbs CC49 and CC83 was between 5% and 24%; however, unlike MAb B72.3, greater numbers of neoplasms that stained positively with MAbs CC49 and CC83 had higher percentages of stained cells (2549%) ( Table 1 ). All neoplasms positive for MAb B72.3 were also positive for MAbs CC49 and CC83. The tissue distribution and cellular location CC83 were very similar to that of MAb B72.3, but the intensity of staining was generally higher ( Table 1 ).
In serially stained sections, similar groups of neoplastic urothelial cells stained with the three different TAG-72 antibodies (Fig. 3 ). MAb B72.3 did not appear to react with a different group of cells than did MAbs CC49 and CC83; however, MAbs CC49 and CC83 appeared to stain a larger population of neoplastic urothelial cells ( Fig. 3) .
Of the neoplasms designated as negative, 14 of 19 of the samples negative for MAb CC49 and 17 of 24 of the samples negative for MAb CC83 contained low numbers of stained neoplastic urothelial cells. The staining observed in these negative samples was similar to that described for staining in samples negative for MAb B72.3.
In this study, none of the normal urinary bladders and none of the hyperplastichflamed urinary bladder samples stained with MAbs B72.3, CC49, or CC83.
Discussion
A majority of the canine transitional cell carcinomas of the urinary bladder stained positively for MAbs B72.3, CC49, and CC83, indicating that an antigen similar to TAG-72 is expressed in canine neoplastic urothelial cells. These findings are in agreement with the results of a preliminary study in which 54% of canine transitional cell carcinomas of the urinary bladder stained positively with MAb B72.3.3 In both studies, most neoplasms positive for MAb B72.3 had a multifocal tissue staining pattern and 5 4 4 % cellular staining.
Although the percentage of cellular staining of these transitional cell carcinomas of the urinary bladder was not high, the staining of MAb B72.3 was specific for neoplastic urothelial cells. Neither mesenchymal tissue nor inflammatory cells stained with MAb B72.3, even when present within sections that contained positively stained neoplastic cells. Additionally, neither normal urinary bladders nor hyperplastichflamed urinary bladders stained with MAb B72.3. These findings are in contrast to those of studies in human beings that have shown that low numbers of normal and hyperplastic urothelial cells react with MAb B72.3.I7J8 In human beings, MAb B72.3 has been used as a marker for neoplastic epithelial cells in effusions and fine needle aspirate^,'^,^^,^' but its application in urine samples has not been reported. Results of the present study imply a potential use of MAb B72.3 as a marker for neoplastic urothelial cells in cytospin preparations from dog urine. However, a potential problem with the use of MAb B72.3 as a marker for neoplastic urothelial cells is that this antibody does not uniformly stain all neoplastic cells; therefore, the sensitivity of MAb B72.3 in detecting a small number of neoplastic urothelial cells in a urine sample might be lower than desired. A prospective study would be needed to address this question, particularly because only 5-24% of cells usually stained.
Staining of canine transitional cell carcinoma of the urinary bladder with MAb B72.3 does not appear to be related to specific features of malignancy, including DNA ploidy, clinical stage, histologic grade, or presence of vascular and/or lymphatic invasion. This finding suggests that staining with MAb B72.3 lacks prognostic significance. A similar lack of prognostic significance for MAb B72.3 staining has been reported Vet Pathol 3 2 2 , 1995 for colonic, ovarian, and endometrial carcinomas in human being^.^'-^^ In this study, the finding that similar groups of neoplastic cells in serial sections stained with MAbs B72.3, CC49, and CC83 suggests that all three antibodies are binding to the same antigen. This antigen is probably similar to TAG-72 because these three antibodies bind to different carbohydrate epitopes on TAG-72.I3 The epitope that binds MAB B72.3 has been identified as sialosyl-Tn (0-linked sialosyl-2,6 a-N-acetylgalacto-~aminyl),~J' whereas the epitopes of MAbs CC49 and CC83 have not been fully characterized. Because these antibodies might be cross-reacting with epitopes on an antigen other than TAG-72 (but having an identical distribution), isolation and biochemical evaluation of this tumor-associated antigen in canine transitional cell carcinoma of the urinary bladder is needed.
The results of the present study also demonstrated that MAb CC49 has a higher affinity for canine transitional cell carcinoma of the urinary bladder than does MAb B72.3. Other investigators have reported superior immunoreactivity of MAb CC49 over MAb B72.3 for several types of human c a r c i n~m a s .~J~ The superior immunoreactivity of MAb CC49 could be due to a more abundant or more accessible epitope or to the higher K, of MAb CC49.I9 Similar explanations could be used for the differences in staining reactivity between MAbs CC83 and B72.3.
The staining observed in some neoplasms designated as negative was not attributed to nonspecific background staining or cross-reactivity with another cell type because the staining of these negative samples was limited to neoplastic urothelial cells. These neoplasms are probably weakly expressing an antigen recognized by MAbs B72.3, CC49, and CC83 but at a level below the sensitivity of the standard ABC immunoperoxidase method used in this study. Alternatively, the processes of formalin fixation or paraffin embedment may have denatured the antigen to which these antibodies bind. In this study, the finding that trypsinization did not substantially change the percentage of cellular staining in these negative samples suggests that significant antigen denaturation did not occur. Other investigators have also demonstrated that formalin fixation and paraffin embedment did not adversely affect MAb B72.3 staining in human tissues. 28 The effect of formalin fixation on the staining of canine transitional cell carcinomas with MAbs B72.3, CC49, and CC83 should be further evaluated because the time of formalin fixation of the samples used in the present study was unknown and presumably varied.
The present study demonstrated that MAb B72.3 binds to an antigen in neoplastic urothelial cells that is similar to TAG-72 and that the expression of this antigen is not related to the presence of other features of malignancy, such as the histologic grade, clinical stage, or DNA ploidy. These results suggest that MAb B72.3 has diagnostic but not prognostic value for canine transitional cell carcinoma of the urinary bladder. This study also demonstrated that MAb CC49 may be better than MAb B72.3 as a marker of neoplastic urothelial cells. Further investigation of the immunoreactivity of MAb CC49 with other normal and neoplastic canine tissues is needed to better define its usefulness in diagnostic veterinary medicine.
